Breaking News

Altamira, Univercells Partner on Nanoparticle-Delivered mRNA Vaccines

Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Altamira Therapeutics Ltd., a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, has entered into a collaboration agreement with Univercells Group to evaluate the use of the company’s SemaPhore platform for the delivery of mRNA vaccines. Univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mRNA vaccines and therapeutics.   Under the agreement, Univercells will test in vitro and in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters